Literature DB >> 16583185

Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis.

A Bal1, E Unlu, G Bahar, E Aydog, E Eksioglu, R Yorgancioglu.   

Abstract

Ankylosing spondylitis (AS) is a chronic, inflammatory, rheumatological disease affecting primarily the sacroiliac joint and vertebral column, with an etiology that remains obscure. Cytokines are soluble proteins that have specific roles in inflammatory response, arranging the interaction between cells of the immune system both in natural and specific immune reactions. This study was planned to evaluate the relation between the level of cytokines and the clinical and laboratory findings of patients with AS compared to healthy subjects. In this study, we demonstrated increased serum levels of soluble interleukin-2 receptor (sIL-2R), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in patients with AS compared with healthy subjects. Only IL-1 beta levels were not increased in AS patients. We found a correlation between C-reactive protein and IL-6 levels and between erythrocyte sedimentation rate and sIL-2R, IL-6 and TNF-alpha levels. Only the sIL-2R level was correlated with Bath AS Metrology Index and Bath AS Functional Index. We suggest that sIL-2R, IL-6, and TNF-alpha may have a role in the pathogenesis of AS and that their serum levels can be used as disease activity parameters and tools for diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16583185     DOI: 10.1007/s10067-006-0283-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  20 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies.

Authors:  P Claudepierre; J C Rymer; F J Authier; Y Allanore; B Larget-Piet; R Gherardi; X Chevalier
Journal:  Br J Rheumatol       Date:  1997-03

3.  Serum levels of IL-1 beta, TNF-alpha, IL-8, and acute phase proteins in seronegative spondyloarthropathies.

Authors:  Birkan Sonel; Hüseyin Tutkak; Nursen Düzgün
Journal:  Joint Bone Spine       Date:  2002-10       Impact factor: 4.929

4.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Elevated serum interleukin-2 receptor; increased in vitro immunoglobulin synthesis and lack of response to testosterone-enhanced in vitro interleukin-2 production in ankylosing spondylitis.

Authors:  H C Liu; K H Hsieh
Journal:  Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi       Date:  1987-02

6.  Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies.

Authors:  E Toussirot; P Lafforgue; J Boucraut; P Despieds; A Schiano; D Bernard; P C Acquaviva
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

7.  Ankylosing spondylitis: the correlation between a new metrology score and radiology.

Authors:  L G Kennedy; T R Jenkinson; P A Mallorie; H C Whitelock; S L Garrett; A Calin
Journal:  Br J Rheumatol       Date:  1995-08

8.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

9.  Interleukin 1 and interleukin 2 generation by peripheral blood cells from patients with ankylosing spondylitis.

Authors:  E C Keystone; S Jaglal; A Shore
Journal:  J Rheumatol       Date:  1986-10       Impact factor: 4.666

Review 10.  Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review.

Authors:  C Keller; A Webb; J Davis
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

View more
  52 in total

Review 1.  Biomarkers in spondyloarthritis.

Authors:  Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

Review 2.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

Review 3.  Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

4.  The effect of IL-4 and MTHFR gene variants in ankylosing spondylitis.

Authors:  S Yigit; A Inanir; S Tural; B Filiz; A Tekcan
Journal:  Z Rheumatol       Date:  2015-02       Impact factor: 1.372

Review 5.  The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis.

Authors:  Judith A Smith
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

6.  Application of molecular, microbiological, and immunological tests for the diagnosis of bone and joint tuberculosis.

Authors:  Yinghua Tang; Lianli Yin; Shifu Tang; Hongyu Zhang; Jihui Lan
Journal:  J Clin Lab Anal       Date:  2017-05-22       Impact factor: 2.352

7.  Osteoporosis Management in Ankylosing Spondylitis.

Authors:  Alicia M Hinze; Grant H Louie
Journal:  Curr Treatm Opt Rheumatol       Date:  2016-10-05

8.  A synthetic peptide derived from A1 module in CRD4 of human TNF receptor-1 inhibits binding and proinflammatory effect of human TNF-alpha.

Authors:  Yingnan Cao; Zhaohe Wang; Xianzhang Bu; Shu Tang; Zhengrong Mei; Peiqing Liu
Journal:  Inflammation       Date:  2009-06       Impact factor: 4.092

9.  The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis.

Authors:  Ingo H Tarner; Ulf Müller-Ladner; Christine Uhlemann; Uwe Lange
Journal:  Clin Rheumatol       Date:  2008-12-17       Impact factor: 2.980

10.  Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis.

Authors:  Wei Liu; Yuan-Hao Wu; Lei Zhang; Xiao-Ya Liu; Bin Xue; Yi Wang; Bin Liu; Qiao Jiang; Hou-Wen Kwang; Dong-Jing Wu
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.